Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89,266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.
Chu T, Yuan J, Lu J, Nie W, Zhong R, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Zhang X, Teng J, Gao Z, Lou Y, Li J, Qiang H, Zhang C, Li J, Xia X, Zhong H, Han B. Chu T, et al. Among authors: zhang b, zhang c, zhang w, zhang x, zhang y. Clin Transl Med. 2023 Jun;13(6):e1277. doi: 10.1002/ctm2.1277. Clin Transl Med. 2023. PMID: 37254636 Free PMC article. No abstract available.
Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X. Zheng L, et al. Among authors: zhang w, zhang x. Front Immunol. 2023 Jan 26;14:1094378. doi: 10.3389/fimmu.2023.1094378. eCollection 2023. Front Immunol. 2023. PMID: 36776882 Free PMC article.
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
Zhang B, Liu H, Shi C, Gao Z, Zhong R, Gu A, Chu T, Wang H, Xiong L, Zhang W, Zhang X, Yan B, Teng J, Wang W, Bai H, Qiao R, Cheng L, Kuang Y, Zhao R, Zhong H, Han B. Zhang B, et al. Among authors: zhang w, zhang x. BMC Cancer. 2024 Jun 11;24(1):715. doi: 10.1186/s12885-024-12479-0. BMC Cancer. 2024. PMID: 38862908 Free PMC article. Clinical Trial.
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.
Tian W, Ren Y, Lu J, Jing C, Zhang W, Li H, Wang T, Hou Z, Yang T, Zhu W, Zhang Y, Shan B, Yang H, Cheng X, Wang H. Tian W, et al. Among authors: zhang w, zhang y. BMC Med. 2024 Aug 26;22(1):344. doi: 10.1186/s12916-024-03564-z. BMC Med. 2024. PMID: 39183277 Free PMC article. Clinical Trial.
89,266 results
You have reached the last available page of results. Please see the User Guide for more information.